{"ticker": {"uuid": "e400f18d-1e76-4cd9-9112-a1ac88d1ed08", "symbol": "CADL", "name": "Candel Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Candel Therapeutics Reported Better-Than-Feared Q1 Loss \u2013 But All Eyes Turn To This Pivotal Event Tomorrow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZ3QyY0dHNzZEb19hUG5ReXB4Vm42Y1Jud21oWlp3anZyZS1weFJRT01iQzRSNFJEb0FqbGIyMGNCVnFOakxpR2FZSU51QjFRSVl4N0JScmlqRjRaTTJmeGJkZ1Zvel9EYmhBZ2tUdm5meTRnRURUV3pTZzM1SFJWUHRCZFpJMVVQMHAwLUd0NmI0WGQtZ1U1aWZraThZYUlYaEpoMFNjaG9RMFkxM3NzUjVNQlZfX002UnF1OEpR?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T22:48:06+00:00", "published_display": "16 Jul 2026 22:48", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dow, S&P 500, Nasdaq Futures Rise As Traders Eye Supreme Court Tariff Verdict, GDP Data: Why GRAL, RIG, CADL, CELH, ARDX Are Trending", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPeDgtei1fb0tYUWpIZ2Nwai11VjFuX0EzbXJRYTVTNkxQN1B4VXY2V09qdUVjLU9HeG9keDR4cEpUeWRoYU1BSU1MTm14NEFZQmdDd05oWFBlbVpNdGV4Y3k5dDF0b2lsQ1d4S1dvTUV2bW9ZSVlFSy1uS3dyNm9kaFhkMEZpRzFLa2R4alhqUVNPNnhwY0hzdDY3T3RQZEdFbEF5UzNpMGIxZmc1ZzVPbldTREpPSFNlOG0wcVYxcE9ELV9WdnlydUxBV0pJbFVNNkE?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T21:58:26+00:00", "published_display": "14 Jul 2026 21:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (CADL) Price Events", "summary": "This article provides an AI-generated analysis of Candel Therapeutics Inc. (NASDAQ: CADL) price events, highlighting weak near-term sentiment with potential shifts in mid and long-term outlook. It details specific institutional trading strategies (Position, Momentum Breakout, and", "url": "https://news.stocktradersdaily.com/news_release/81/Liquidity_Mapping_Around_CADL_Price_Events_071326065601_1783983361.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T18:56:00", "published_display": "13 Jul 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel initiates Candel Therapeutics stock with buy, $22 target", "summary": "Stifel initiated coverage on Candel Therapeutics Inc. (NASDAQ:CADL) with a Buy rating and a $22.00 price target, significantly higher than its current stock price. The firm's positive outlook is based on the company's aglatimagene therapy, a clinically validated viral immunothera", "url": "https://www.investing.com/news/analyst-ratings/stifel-initiates-candel-therapeutics-stock-with-buy-22-target-93CH-4787503", "source_name": "Investing.com", "published_at": "2026-07-13T14:12:51", "published_display": "13 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CADL Initiates Coverage On Candel Therapeutics by Stifel -- Buy Rating Issued", "summary": "Stifel analyst Stephen Willey has initiated coverage on Candel Therapeutics (CADL) with a \"Buy\" rating and a price target of $22.00, significantly above its current trading price of $9.47. Despite this optimistic outlook, Candel Therapeutics holds a low GF Score\u2122 of 25/100, indic", "url": "https://www.gurufocus.com/news/8955013/cadl-initiates-coverage-on-candel-therapeutics-by-stifel-buy-rating-issued", "source_name": "GuruFocus", "published_at": "2026-07-13T10:41:49", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel hands its new commercial chief 285,000 options", "summary": "Candel Therapeutics (Nasdaq: CADL) announced that it granted 285,000 stock options to its new Chief Commercial Officer, Mark Sims, under Nasdaq Listing Rule 5635(c)(4) and the company's 2025 Inducement Plan. The options have an exercise price of $10.03, matching the Nasdaq closin", "url": "https://www.stocktitan.net/news/CADL/candel-therapeutics-announces-inducement-grant-under-nasdaq-listing-3lmnt38npk1g.html", "source_name": "Stock Titan", "published_at": "2026-07-09T00:13:15", "published_display": "09 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3", "summary": "Candel Therapeutics, Inc. (CADL) filed a Form 3 to list Mark E. Sims as its Chief Commercial Officer. This initial statement of beneficial ownership indicates no share transactions or holdings for Sims, with zero reported purchases or sales. The filing serves to establish Sims's ", "url": "https://www.stocktitan.net/sec-filings/CADL/form-3-candel-therapeutics-inc-initial-statement-of-beneficial-owners-38d905860008.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:17", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Candel Therapeutics, Inc. Insider Trading Activity", "summary": "Candel Therapeutics, Inc.'s Chief Commercial Officer, Mark E. Sims, was granted 285,000 stock options with an exercise price of $10.03 per share, expiring on July 6, 2036. The options will vest 25% on July 6, 2027, with the remainder vesting in 36 equal monthly installments, cont", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-d4a3b02add5c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:17", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Candel Therapeutics announced the grant of stock options to Mark Sims, its new Chief Commercial Officer, as an inducement for his employment. The grant, totaling 285,000 shares with an exercise price of $10.03, was made on July 6, 2026, under the Company's 2025 Inducement Plan. T", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324419/0/en/candel-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T16:05:00", "published_display": "08 Jul 2026 16:05", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQQ1RMNi1SZ0lSdzkxS1c4YVRCbER5UEN5TmdFM1RvMjMtVkdQalhHN2tRbW9lOFp0VmdyWlJsQVB5ejkwVndhdkI5c2d5Qi15R2RrWTdBTjZuSTlVaWxuM01wQU43TXV0Y3Z6YmpCSVhBT0Jjbmd3R1V0bTA0VzU3ZUNSM3ktWnlPOU9vQjNKMGM4WkxUZmQ3bnlmRXc0YmQ0bVBXNGJuRk9Jd0N1Y19HakljRQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)", "summary": "Two healthcare companies, Candel Therapeutics (CADL) and Ibio (IBIO), have received bullish sentiments from analysts. Citi analyst Yigal Nochomovitz maintained a Buy rating on Candel Therapeutics with a $26.00 price target, while Keay Nakae from Chardan Capital reiterated a Buy r", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IBIO/pressreleases/3111524/analysts-offer-insights-on-healthcare-companies-candel-therapeutics-cadl-and-ibio-ibio/", "source_name": "The Globe and Mail", "published_at": "2026-07-03T10:40:43", "published_display": "03 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) director receives fully vested 381-option equity grant", "summary": "Candel Therapeutics director Nicoletta Loggia received a fully vested grant of 381 stock options with an exercise price of $10.30 per share, expiring on June 30, 2036. This grant was issued as compensation in lieu of normal quarterly cash payments. Following this transaction, Log", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-45d9a36b6bb0.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:10:09", "published_display": "01 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics CSO Francesca Barone sells $235k in stock", "summary": "Francesca Barone, Chief Scientific Officer of Candel Therapeutics, Inc. (NASDAQ:CADL), sold 23,447 shares of company stock for approximately $235,768 on June 29, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale followed a period of strong stock perf", "url": "https://www.investing.com/news/insider-trading-news/candel-therapeutics-cso-francesca-barone-sells-235k-in-stock-93CH-4771527", "source_name": "Investing.com", "published_at": "2026-07-01T21:09:06", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Candel Therapeutics Inc For: 1 July By Investing.com", "summary": "This article announces a Form 4 filing for Candel Therapeutics Inc. for July 1st. It also includes various market data, trending stocks, and popular news articles from Investing.com, along with promotions for their investing tools.", "url": "https://ca.investing.com/news/stock-market-news/form-4-candel-therapeutics-inc-for-1-july-93CH-4717026", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:40:49", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options", "summary": "Candel Therapeutics director Paul B. Manning received a grant of 2,199 stock options as compensation, which are fully vested upon grant and replace normal quarterly cash payments. These options allow him to purchase shares at an exercise price of $10.30 per share. This transactio", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-63c04fbf6df7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:49", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) director receives fully vested option award", "summary": "Candel Therapeutics director Joseph C. Papa received a fully vested stock option award of 1,331 options to purchase common stock at an exercise price of $10.30 per share. This grant was issued in lieu of regular quarterly cash payments and is immediately exercisable, allowing him", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-a6a495b4e746.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:49", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Candel Therapeutics announced the grant of inducement stock options to a new employee for 25,000 shares of common stock at an exercise price of $10.30 per share. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment and will vest", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2377112", "source_name": "The Manila Times", "published_at": "2026-07-01T20:09:06", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel grants new employee 25,000 stock options at $10.30", "summary": "Candel Therapeutics (CADL) has granted 25,000 inducement stock options to a new employee at an exercise price of $10.30 per share. This award, under the company's 2025 Inducement Plan, vests 25% after one year and the remaining 75% over 36 monthly installments, contingent on cont", "url": "https://www.stocktitan.net/news/CADL/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rolx3xan7yat.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:40:49", "published_display": "01 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics initiates phase 3 lung cancer trial", "summary": "Candel Therapeutics (NASDAQ:CADL) has launched its global phase 3 AURORA trial for metastatic non-squamous non-small cell lung cancer, combining aglatimagene besadenovec plus valacyclovir with pembrolizumab. This follows a successful phase 2 trial and Fast Track Designation from ", "url": "https://www.investing.com/news/company-news/candel-therapeutics-initiates-phase-3-lung-cancer-trial-93CH-4767779", "source_name": "Investing.com", "published_at": "2026-07-01T10:13:00", "published_display": "01 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) CSO executes 23,447-share open-market sale under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRDYzdE56Q3RJYW44NVN2RjNzMGhzN0ZaMll0RHB1ZV9FT3JubWZBcmJYbkc5ZmZPZDRaeWM1T3lQeFBwdlJzeVdSWVNYWGl3bGFpR1FzZVJ3NHFWYi1zeUhXMS1iVU1jcnJqT3I0U2Z0V2c1YjdvZEdXWEw1Y25HNEJqdk1td1k4MjFDTnpkc2JhUzQ5SS1JU215WUxRV2ZzRDBUQUgxLXNZbk9ESHhhUTJJekM3dmhx?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Candel Therapeutics, Inc. \u2013 NASDAQ:CADL", "summary": "This page from TradingView provides financial information for Candel Therapeutics, Inc. (NASDAQ: CADL), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of viewing, with no trades executed.", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:13:18", "published_display": "01 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com", "summary": "Candel Therapeutics (NASDAQ:CADL) has launched its global phase 3 AURORA trial for metastatic non-squamous non-small cell lung cancer, combining aglatimagene besadenovec with valacyclovir and pembrolizumab. The stock surged 83% in six months, nearing its 52-week high, reflecting ", "url": "https://m.za.investing.com/news/stock-market-news/candel-therapeutics-initiates-phase-3-lung-cancer-trial-93CH-4349748?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T17:11:27", "published_display": "30 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel opens global phase 3 AURORA trial in lung cancer", "summary": "Candel Therapeutics has initiated the global pivotal phase 3 AURORA trial for aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer (NSCLC) patients who progressed after immune checkpoint inhibitors and chemotherapy. The trial aims to assess overall survival,", "url": "https://www.stocktitan.net/news/CADL/candel-therapeutics-announces-initiation-of-global-pivotal-phase-3-4u79q49k78ds.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:11:27", "published_display": "30 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors", "summary": "Candel Therapeutics has initiated its global pivotal Phase 3 AURORA trial for aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer (NSCLC) patients who show an inadequate response to immune checkpoint inhibitors. The trial will compare CAN-2409 in combinatio", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/candel-therapeutics-announces-initiation-of-global-pivotal-phase-3-aurora-trial-evaluating-aglatimagene-besadenovec-can-2409-in-advanced-non-small-cell-lung-cancer-patients-with-inadequate-response-to-immune-checkpoint-inhibitors/2375759", "source_name": "The Manila Times", "published_at": "2026-06-30T12:11:27", "published_display": "30 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Candel Therapeutics, Inc. (CADL) on June 29, 2026, which is categorized as neutral in impact and sentiment. The filing details the proposed sale of 7,000 common shares with an aggregate market value of $68,530.00, acquired on Janua", "url": "https://www.stocktitan.net/sec-filings/CADL/144-candel-therapeutics-inc-sec-filing-f0a4cdebc1cf.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:44:44", "published_display": "29 Jun 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics appoints Mark Sims as Chief Commercial Officer", "summary": "Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026. Sims, with 25 years of oncology commercial experience from AstraZeneca, Novartis, and Merck, will lead the commercial strategy and launch readiness for aglatimagene besadenovec (CAN-2", "url": "https://pmlive.com/pharma_news/candel-therapeutics-appoints-mark-sims-as-chief-commercial-officer/", "source_name": "PMLiVE", "published_at": "2026-06-29T12:09:44", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Candel Therapeutics, Inc. \u2013 NASDAQ:CADL", "summary": "This article displays the \"Price to sales forward\" metric for Candel Therapeutics, Inc. (NASDAQ: CADL). It is a brief financial data point from TradingView, which provides market and reference data from ICE Data Services and FactSet Research Systems Inc. The content itself is ver", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:24", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics, Inc. Actuals & Estimates (NASDAQ:CADL)", "summary": "This article provides an overview of Candel Therapeutics, Inc. (NASDAQ: CADL) stock, including its current price, historical performance, analyst forecasts, and key financial data. It highlights the company's strong stock performance over the past year, with a 96.59% increase, an", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:25", "published_display": "26 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CADL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Candel Therapeutics, Inc. (CADL) stock, including analyst price targets and future predictions. It details the company's financial performance, stock volatility, market capitalization, and upcoming earnings report, along with historical price ", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:44", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Candel Therapeutics, Inc. \u2013 BOATS:CADL", "summary": "This article focuses on the enterprise value to revenue forward for Candel Therapeutics, Inc. (CADL) without providing specific financial figures. It appears to be a stub or a financial data page from TradingView. The content primarily consists of navigation, copyright informatio", "url": "https://www.tradingview.com/symbols/BOATS-CADL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:47", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer", "summary": "Candel Therapeutics has announced the appointment of Mark Sims as its Chief Commercial Officer. Sims brings over 25 years of biopharmaceutical experience, including significant leadership roles at Amgen and Gilead, and is expected to drive the company's commercial strategy, parti", "url": "https://www.moomoo.com/news/post/72035851/press-release-candel-therapeutics-appoints-mark-sims-as-chief-commercial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T21:09:44", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Designates Mark Sims as CCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOblc3Mm5KSk9vVjBPM3NqdVF6b09YejlSU1BSU2ZHREZuOWZNZzEya3BEOU1hV0RURWwyeXNvYUhVNTBib3AyclJobkVNUUFMbVQ0VmdKcXhLc3lkSW1oVDctMDY1YjJKOEZjenByRnYzeGQyY29DMDlaMm1QcjQtbEpYREFUaHR2cDVmY3BUMEtISXpLLVlWSFUybFdveTNEX09j?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics names Mark Sims as chief commercial officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNb0tXTnBFYkgyZ0Mtc25VNmEtS2dTRVU0SGlHeEpadkwyUS1uVGtfWF9mcWMxeEV4S3owSjNRT3ZaZ2NrQjMyc1lUX1lKU3k5VUtETjc0UjBxUGtsTmpPaFNjeVJUNmZhQndKd3VvcGItQUFUVHJlbndNYVMwTUxfYUwxM2VneUlwcmV6QjNhQVJLT2NiQXRTSFc1RkpmeVoxbGNrUDhab3NBc2RIb0s0MGNfdXZ5V21XOENHRg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel hires oncology veteran ahead of 2026 prostate cancer launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQY21XNnZycXBzd1cyeWVMTU1NLW9YdGY4ODhBbGthSHJnTjZ1Y3BURTdLa1hSZS0tQWV5eld6MTRtYjdRREJWYzhuQWlxUXctbXBWMVZEdDJ0WVZ1SHhDZTgtZjFFS2lvR1gwcXV1QVZQZjVjN2ZUVVljZVRyLTUxWTdxbGJxSndqejJmR2MyYXBIUFFRRUFoaHRNNDNYdjEwNFotWjFGTlJQU0VnWEpzMVh6SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Diem Nguyen awarded 32,000 Candel Therapeutics (CADL) stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPb1habm9Gc0Q3RzFlb0hCMVpfRzgwQnRIQTl1c0VaRU5OTVhtSlU4VzNrVnl5TWtjVUxYZ3dDbFZmbFBFYnRiRm1HLTIyallEQXp1MllNZzdyTlV5dEdhTU5YWVk1cGNBeTh0X0YtMXZKd2o2Nkw2YUVUN3l2bjlieTJBZmtQNUNfOE95aVdnTTRVWVJ4WW5ZeXJMVUZQc2NBeVlrQ1dCMUEtejZFNGJRbnEyNkM4cWli?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (NASDAQ: CADL) director awarded 32,000 options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPcWstMHpvQlhPUWhFSXFmQVROY19JZ0lYc3ZlRGVYTTh1U1NJLVVWM1BuZ2lrOGszWjFWbUdtZUk2TjNVSUhFVHhTMzRCVy1nTEJ0NEdTVlNvTW1hYWxXTVZCOVUyd3pTVV9FQk83bUdWYldvdy1lR2loLXZQdDI2QWpydmdaZ3ZzQ3lQUTZ2emF6VnFudjliZGJmLTdQQ3RSVTJpWGVMbTV1OGMyZGpKV1BuSEZ3dXJv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/candel-therapeutics-announces-publication-lancet-120500034.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:05:00+00:00", "published_display": "02 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New hires at Candel Therapeutics get 63,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcVZqVmhGeWtVY3BHMVNoZjFJMXFqdUhsN0ZaY20takYzcnpfa3dYTlFrc1laSTkyemU1WHBSamRHWkdYalh1OFdqSXVlRUJ6Z3VBalpZdEswUXdRWWlaR3ZUelhENEk0STBiWkgyOGtTMG91YkxJeUw1Z2d3MlFva1h3dVBQYlhkY1ZpamNFUGwtNFRCMzJhcU5DaFNNSWFmNmpCQXdIWmFsOUt6dXNrOFhBUkcwV1N1VHRNeEV4NDM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data", "summary": "", "url": "https://finance.yahoo.com/m/e4d69008-1eb2-3326-af76-22f9b38364a3/candel-therapeutics-eyes.html", "source_name": "MarketBeat", "published_at": "2026-05-20T15:13:00+00:00", "published_display": "20 May 2026 15:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSkpXdklWME51Um5YbXBPaXdtTFRYZXFXQjZ5Z253aVlRYTN1bWNPMWFQNFZrX1FSS3NURENSajFDakI0bkpiVFo0eWdoRmZQVVJOZUViVWFhdEE4MWc5QjlySVA3OEoyU0dNeW9VcWpQZGQ5dTgyWFQwTEY5MllzV3VyUThKQllpWDRoaWdWYm1QalBqTU5hRzl4ZDJqMGNuNWc?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 prostate cancer data highlight Candel Therapeutics (NASDAQ: CADL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOUmdsOTVheXJ1dVhIeWliR0toRlhWNTl2YUR0eDRkRFZNR0ZiYmgwYVVjZmpNTWwzdFo1dWpGc2N1UFRDdEd3T1puWjFJaGNaVjlPYVhOX1hFcWFXMFZ1RFRPM0ZSUDg1eDRfbkN3a2txQjcySlpfamY2cW9hUFVmdWtpRDdmVVo3WnB3S29KYld3YnJQZHBNYWVPR2RmLTZJdmVZM1BLam5OWjhCWS1DSXd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Two new Candel hires get options to buy 29,400 shares at $6.18", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZGpKRV9hTW9ITUZhZV9QRUc5WHl3TE5aVER2amxTQ3ViWWc1cnNhcnRubU1sR01ySlBMcXV1SS1SSFJsWGVKcE91S1Q4V1hxX3gxRlFfS053TmxMeWoyejVtcC1pNHhqejN4LWRMN3YxYUkyeGo5UG1iVzVCZzVhTUdnTzF3VlBGSnRoZVlRZk1iTGRoakhqUElka1VXbDZvQm1KT3piVEhOTnp3eWc2eUNQenlrc1Ayei1JTl92V1A?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel picks EVERSANA over building its own sales force for prostate launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPeDFlbGpoWGFzWktQVFdLTXRURGRreXZDQ3d1UzY0ejdQWTFCaWJvam5vdEtZeGQ0YWZCc1RmRHNqLURVZngxdDFuRG1sdE9UaU5RNUU0dm92NGpRdlRaME5keVJkbExGd1hmSDJ3RTJ6NURVMENqai16Wm1FRjlQMFhNa3UxT2l1T1pLeVdQcmN2R1Z3Y0p2NklaMzIwRDBPTXNUMDZzS05nOFJlQndHSEN4WVNJcWFu?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVm5ad2pGWGplcTdaNkM3NlNXenNxNlk4UUJPbVpwZWNxS3BOR0YwalRCbGFnVF9Ga3BZU3VIaTNuNnduaUE4aGRHYjA0UEhTdXk1bVl2Ym5KbUNyMDBSTUU2M05INVJqc2wwclI2MHBzR1UtbTdQS0U5Smg5TmhjQmFYMHVGSkZmZkxxZkpOR1pHWl95cllTdjFOYW1TUWFUUXZHX1VsZ1A?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report\u2014Grail, Candel", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQaUJEWURHeVJpYzNaV1NKLXF2TW5MQ1hqaUJrZ1BfRVRyTTZuRFR5dzZjajBudF9fR3A5QmUxQ0NDd1UwWDdFTUpNYmw2YUgtMlZEaVE0RXMtSTN1X19FNE01Q1BuLUJjeEFuMHJIenNQUThiS3pybFFWQUstS0E1R3pHOGk1NWZmUjN2QXA2bDBhLXRBWmlrZWdmbkVXLVZuellJaTZPeXl5dktkc1VlUW56cDQyQld2ZTU1UGhwZE9OYU9aMkVxSms1bEtjLWZTLXJCSWpxMDBkRDR1XzVYLVVCV0V6M2lHZkZ4QldGdVhsck9YOWFIUlhjd1E1Tndo?oc=5", "source_name": "Benzinga", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxONU1rSzBKczVDT3VjcW0zaUpmdVVvVGtOMGg5czhCcXk0RFBNcmR2MTdONjZUV0k0Zi1DbjJnaGdEOUhyTGZpTzI0dnhfdTcxSWxzSlUzNkgtYWhiWnA4TUkzOXBKcmVNQWNyQzZxX2p2ejh5WXNzeC1DN0gxdlp0aWFHTFNFNVJqZU81aXczN1lPVVNzelJTU0NmbloxSWpWNFctcnhCS0ZhNWFaM3FiLS0yb1A2dndWWWRCUkxwUENrY0JBci1EeGlkMTRucjdFTkNzTU5lOGRGamx4TG5GeWZrb0dPRTh4NjA4YThwZ3BYUHBtLTZOZHpNb21PZw?oc=5", "source_name": "Proactive financial news", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcVVpTFh4d0hqVnhSZW54YWFmRUgwUWJBVXdnaktVNU9MUVpxeWZNaVo1QkFSbDhaOHhPanByY3lCYi1vSVdBdzM2Y09mWGswVFhZTjcwdW5WRnZKaE9nMjhfTjN3TC1TNFp3V0ptOTZaVXN4UXhzbS1UZGJDdW41VkRhSXFTWXpKYlpfZWJ2dUZNWVZGNi1GRGhEbFZXUQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-02-07T08:00:00+00:00", "published_display": "07 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Candel Therapeutics Reported Better-Than-Feared Q1 Loss \u2013 But All Eyes Turn To This Pivotal Event Tomorrow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZ3QyY0dHNzZEb19hUG5ReXB4Vm42Y1Jud21oWlp3anZyZS1weFJRT01iQzRSNFJEb0FqbGIyMGNCVnFOakxpR2FZSU51QjFRSVl4N0JScmlqRjRaTTJmeGJkZ1Zvel9EYmhBZ2tUdm5meTRnRURUV3pTZzM1SFJWUHRCZFpJMVVQMHAwLUd0NmI0WGQtZ1U1aWZraThZYUlYaEpoMFNjaG9RMFkxM3NzUjVNQlZfX002UnF1OEpR?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T22:48:06+00:00", "published_display": "16 Jul 2026 22:48", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dow, S&P 500, Nasdaq Futures Rise As Traders Eye Supreme Court Tariff Verdict, GDP Data: Why GRAL, RIG, CADL, CELH, ARDX Are Trending", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPeDgtei1fb0tYUWpIZ2Nwai11VjFuX0EzbXJRYTVTNkxQN1B4VXY2V09qdUVjLU9HeG9keDR4cEpUeWRoYU1BSU1MTm14NEFZQmdDd05oWFBlbVpNdGV4Y3k5dDF0b2lsQ1d4S1dvTUV2bW9ZSVlFSy1uS3dyNm9kaFhkMEZpRzFLa2R4alhqUVNPNnhwY0hzdDY3T3RQZEdFbEF5UzNpMGIxZmc1ZzVPbldTREpPSFNlOG0wcVYxcE9ELV9WdnlydUxBV0pJbFVNNkE?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T21:58:26+00:00", "published_display": "14 Jul 2026 21:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (CADL) Price Events", "summary": "This article provides an AI-generated analysis of Candel Therapeutics Inc. (NASDAQ: CADL) price events, highlighting weak near-term sentiment with potential shifts in mid and long-term outlook. It details specific institutional trading strategies (Position, Momentum Breakout, and", "url": "https://news.stocktradersdaily.com/news_release/81/Liquidity_Mapping_Around_CADL_Price_Events_071326065601_1783983361.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T18:56:00", "published_display": "13 Jul 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel initiates Candel Therapeutics stock with buy, $22 target", "summary": "Stifel initiated coverage on Candel Therapeutics Inc. (NASDAQ:CADL) with a Buy rating and a $22.00 price target, significantly higher than its current stock price. The firm's positive outlook is based on the company's aglatimagene therapy, a clinically validated viral immunothera", "url": "https://www.investing.com/news/analyst-ratings/stifel-initiates-candel-therapeutics-stock-with-buy-22-target-93CH-4787503", "source_name": "Investing.com", "published_at": "2026-07-13T14:12:51", "published_display": "13 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CADL Initiates Coverage On Candel Therapeutics by Stifel -- Buy Rating Issued", "summary": "Stifel analyst Stephen Willey has initiated coverage on Candel Therapeutics (CADL) with a \"Buy\" rating and a price target of $22.00, significantly above its current trading price of $9.47. Despite this optimistic outlook, Candel Therapeutics holds a low GF Score\u2122 of 25/100, indic", "url": "https://www.gurufocus.com/news/8955013/cadl-initiates-coverage-on-candel-therapeutics-by-stifel-buy-rating-issued", "source_name": "GuruFocus", "published_at": "2026-07-13T10:41:49", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel hands its new commercial chief 285,000 options", "summary": "Candel Therapeutics (Nasdaq: CADL) announced that it granted 285,000 stock options to its new Chief Commercial Officer, Mark Sims, under Nasdaq Listing Rule 5635(c)(4) and the company's 2025 Inducement Plan. The options have an exercise price of $10.03, matching the Nasdaq closin", "url": "https://www.stocktitan.net/news/CADL/candel-therapeutics-announces-inducement-grant-under-nasdaq-listing-3lmnt38npk1g.html", "source_name": "Stock Titan", "published_at": "2026-07-09T00:13:15", "published_display": "09 Jul 2026 00:13", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3", "summary": "Candel Therapeutics, Inc. (CADL) filed a Form 3 to list Mark E. Sims as its Chief Commercial Officer. This initial statement of beneficial ownership indicates no share transactions or holdings for Sims, with zero reported purchases or sales. The filing serves to establish Sims's ", "url": "https://www.stocktitan.net/sec-filings/CADL/form-3-candel-therapeutics-inc-initial-statement-of-beneficial-owners-38d905860008.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:17", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Candel Therapeutics, Inc. Insider Trading Activity", "summary": "Candel Therapeutics, Inc.'s Chief Commercial Officer, Mark E. Sims, was granted 285,000 stock options with an exercise price of $10.03 per share, expiring on July 6, 2036. The options will vest 25% on July 6, 2027, with the remainder vesting in 36 equal monthly installments, cont", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-d4a3b02add5c.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:17", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Candel Therapeutics announced the grant of stock options to Mark Sims, its new Chief Commercial Officer, as an inducement for his employment. The grant, totaling 285,000 shares with an exercise price of $10.03, was made on July 6, 2026, under the Company's 2025 Inducement Plan. T", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324419/0/en/candel-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T16:05:00", "published_display": "08 Jul 2026 16:05", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQQ1RMNi1SZ0lSdzkxS1c4YVRCbER5UEN5TmdFM1RvMjMtVkdQalhHN2tRbW9lOFp0VmdyWlJsQVB5ejkwVndhdkI5c2d5Qi15R2RrWTdBTjZuSTlVaWxuM01wQU43TXV0Y3Z6YmpCSVhBT0Jjbmd3R1V0bTA0VzU3ZUNSM3ktWnlPOU9vQjNKMGM4WkxUZmQ3bnlmRXc0YmQ0bVBXNGJuRk9Jd0N1Y19HakljRQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)", "summary": "Two healthcare companies, Candel Therapeutics (CADL) and Ibio (IBIO), have received bullish sentiments from analysts. Citi analyst Yigal Nochomovitz maintained a Buy rating on Candel Therapeutics with a $26.00 price target, while Keay Nakae from Chardan Capital reiterated a Buy r", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IBIO/pressreleases/3111524/analysts-offer-insights-on-healthcare-companies-candel-therapeutics-cadl-and-ibio-ibio/", "source_name": "The Globe and Mail", "published_at": "2026-07-03T10:40:43", "published_display": "03 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) director receives fully vested 381-option equity grant", "summary": "Candel Therapeutics director Nicoletta Loggia received a fully vested grant of 381 stock options with an exercise price of $10.30 per share, expiring on June 30, 2036. This grant was issued as compensation in lieu of normal quarterly cash payments. Following this transaction, Log", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-45d9a36b6bb0.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:10:09", "published_display": "01 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics CSO Francesca Barone sells $235k in stock", "summary": "Francesca Barone, Chief Scientific Officer of Candel Therapeutics, Inc. (NASDAQ:CADL), sold 23,447 shares of company stock for approximately $235,768 on June 29, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale followed a period of strong stock perf", "url": "https://www.investing.com/news/insider-trading-news/candel-therapeutics-cso-francesca-barone-sells-235k-in-stock-93CH-4771527", "source_name": "Investing.com", "published_at": "2026-07-01T21:09:06", "published_display": "01 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Candel Therapeutics Inc For: 1 July By Investing.com", "summary": "This article announces a Form 4 filing for Candel Therapeutics Inc. for July 1st. It also includes various market data, trending stocks, and popular news articles from Investing.com, along with promotions for their investing tools.", "url": "https://ca.investing.com/news/stock-market-news/form-4-candel-therapeutics-inc-for-1-july-93CH-4717026", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:40:49", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options", "summary": "Candel Therapeutics director Paul B. Manning received a grant of 2,199 stock options as compensation, which are fully vested upon grant and replace normal quarterly cash payments. These options allow him to purchase shares at an exercise price of $10.30 per share. This transactio", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-63c04fbf6df7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:49", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) director receives fully vested option award", "summary": "Candel Therapeutics director Joseph C. Papa received a fully vested stock option award of 1,331 options to purchase common stock at an exercise price of $10.30 per share. This grant was issued in lieu of regular quarterly cash payments and is immediately exercisable, allowing him", "url": "https://www.stocktitan.net/sec-filings/CADL/form-4-candel-therapeutics-inc-insider-trading-activity-a6a495b4e746.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:49", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Candel Therapeutics announced the grant of inducement stock options to a new employee for 25,000 shares of common stock at an exercise price of $10.30 per share. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment and will vest", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2377112", "source_name": "The Manila Times", "published_at": "2026-07-01T20:09:06", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel grants new employee 25,000 stock options at $10.30", "summary": "Candel Therapeutics (CADL) has granted 25,000 inducement stock options to a new employee at an exercise price of $10.30 per share. This award, under the company's 2025 Inducement Plan, vests 25% after one year and the remaining 75% over 36 monthly installments, contingent on cont", "url": "https://www.stocktitan.net/news/CADL/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rolx3xan7yat.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:40:49", "published_display": "01 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics initiates phase 3 lung cancer trial", "summary": "Candel Therapeutics (NASDAQ:CADL) has launched its global phase 3 AURORA trial for metastatic non-squamous non-small cell lung cancer, combining aglatimagene besadenovec plus valacyclovir with pembrolizumab. This follows a successful phase 2 trial and Fast Track Designation from ", "url": "https://www.investing.com/news/company-news/candel-therapeutics-initiates-phase-3-lung-cancer-trial-93CH-4767779", "source_name": "Investing.com", "published_at": "2026-07-01T10:13:00", "published_display": "01 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (CADL) CSO executes 23,447-share open-market sale under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRDYzdE56Q3RJYW44NVN2RjNzMGhzN0ZaMll0RHB1ZV9FT3JubWZBcmJYbkc5ZmZPZDRaeWM1T3lQeFBwdlJzeVdSWVNYWGl3bGFpR1FzZVJ3NHFWYi1zeUhXMS1iVU1jcnJqT3I0U2Z0V2c1YjdvZEdXWEw1Y25HNEJqdk1td1k4MjFDTnpkc2JhUzQ5SS1JU215WUxRV2ZzRDBUQUgxLXNZbk9ESHhhUTJJekM3dmhx?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Candel Therapeutics, Inc. \u2013 NASDAQ:CADL", "summary": "This page from TradingView provides financial information for Candel Therapeutics, Inc. (NASDAQ: CADL), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of viewing, with no trades executed.", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:13:18", "published_display": "01 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com", "summary": "Candel Therapeutics (NASDAQ:CADL) has launched its global phase 3 AURORA trial for metastatic non-squamous non-small cell lung cancer, combining aglatimagene besadenovec with valacyclovir and pembrolizumab. The stock surged 83% in six months, nearing its 52-week high, reflecting ", "url": "https://m.za.investing.com/news/stock-market-news/candel-therapeutics-initiates-phase-3-lung-cancer-trial-93CH-4349748?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T17:11:27", "published_display": "30 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel opens global phase 3 AURORA trial in lung cancer", "summary": "Candel Therapeutics has initiated the global pivotal phase 3 AURORA trial for aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer (NSCLC) patients who progressed after immune checkpoint inhibitors and chemotherapy. The trial aims to assess overall survival,", "url": "https://www.stocktitan.net/news/CADL/candel-therapeutics-announces-initiation-of-global-pivotal-phase-3-4u79q49k78ds.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:11:27", "published_display": "30 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors", "summary": "Candel Therapeutics has initiated its global pivotal Phase 3 AURORA trial for aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer (NSCLC) patients who show an inadequate response to immune checkpoint inhibitors. The trial will compare CAN-2409 in combinatio", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/candel-therapeutics-announces-initiation-of-global-pivotal-phase-3-aurora-trial-evaluating-aglatimagene-besadenovec-can-2409-in-advanced-non-small-cell-lung-cancer-patients-with-inadequate-response-to-immune-checkpoint-inhibitors/2375759", "source_name": "The Manila Times", "published_at": "2026-06-30T12:11:27", "published_display": "30 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Candel Therapeutics, Inc. (CADL) on June 29, 2026, which is categorized as neutral in impact and sentiment. The filing details the proposed sale of 7,000 common shares with an aggregate market value of $68,530.00, acquired on Janua", "url": "https://www.stocktitan.net/sec-filings/CADL/144-candel-therapeutics-inc-sec-filing-f0a4cdebc1cf.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:44:44", "published_display": "29 Jun 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics appoints Mark Sims as Chief Commercial Officer", "summary": "Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026. Sims, with 25 years of oncology commercial experience from AstraZeneca, Novartis, and Merck, will lead the commercial strategy and launch readiness for aglatimagene besadenovec (CAN-2", "url": "https://pmlive.com/pharma_news/candel-therapeutics-appoints-mark-sims-as-chief-commercial-officer/", "source_name": "PMLiVE", "published_at": "2026-06-29T12:09:44", "published_display": "29 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Candel Therapeutics, Inc. \u2013 NASDAQ:CADL", "summary": "This article displays the \"Price to sales forward\" metric for Candel Therapeutics, Inc. (NASDAQ: CADL). It is a brief financial data point from TradingView, which provides market and reference data from ICE Data Services and FactSet Research Systems Inc. The content itself is ver", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:39:24", "published_display": "27 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics, Inc. Actuals & Estimates (NASDAQ:CADL)", "summary": "This article provides an overview of Candel Therapeutics, Inc. (NASDAQ: CADL) stock, including its current price, historical performance, analyst forecasts, and key financial data. It highlights the company's strong stock performance over the past year, with a 96.59% increase, an", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:25", "published_display": "26 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CADL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Candel Therapeutics, Inc. (CADL) stock, including analyst price targets and future predictions. It details the company's financial performance, stock volatility, market capitalization, and upcoming earnings report, along with historical price ", "url": "https://www.tradingview.com/symbols/NASDAQ-CADL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:44", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Candel Therapeutics, Inc. \u2013 BOATS:CADL", "summary": "This article focuses on the enterprise value to revenue forward for Candel Therapeutics, Inc. (CADL) without providing specific financial figures. It appears to be a stub or a financial data page from TradingView. The content primarily consists of navigation, copyright informatio", "url": "https://www.tradingview.com/symbols/BOATS-CADL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:47", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer", "summary": "Candel Therapeutics has announced the appointment of Mark Sims as its Chief Commercial Officer. Sims brings over 25 years of biopharmaceutical experience, including significant leadership roles at Amgen and Gilead, and is expected to drive the company's commercial strategy, parti", "url": "https://www.moomoo.com/news/post/72035851/press-release-candel-therapeutics-appoints-mark-sims-as-chief-commercial?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-25T21:09:44", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Designates Mark Sims as CCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOblc3Mm5KSk9vVjBPM3NqdVF6b09YejlSU1BSU2ZHREZuOWZNZzEya3BEOU1hV0RURWwyeXNvYUhVNTBib3AyclJobkVNUUFMbVQ0VmdKcXhLc3lkSW1oVDctMDY1YjJKOEZjenByRnYzeGQyY29DMDlaMm1QcjQtbEpYREFUaHR2cDVmY3BUMEtISXpLLVlWSFUybFdveTNEX09j?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics names Mark Sims as chief commercial officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNb0tXTnBFYkgyZ0Mtc25VNmEtS2dTRVU0SGlHeEpadkwyUS1uVGtfWF9mcWMxeEV4S3owSjNRT3ZaZ2NrQjMyc1lUX1lKU3k5VUtETjc0UjBxUGtsTmpPaFNjeVJUNmZhQndKd3VvcGItQUFUVHJlbndNYVMwTUxfYUwxM2VneUlwcmV6QjNhQVJLT2NiQXRTSFc1RkpmeVoxbGNrUDhab3NBc2RIb0s0MGNfdXZ5V21XOENHRg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel hires oncology veteran ahead of 2026 prostate cancer launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQY21XNnZycXBzd1cyeWVMTU1NLW9YdGY4ODhBbGthSHJnTjZ1Y3BURTdLa1hSZS0tQWV5eld6MTRtYjdRREJWYzhuQWlxUXctbXBWMVZEdDJ0WVZ1SHhDZTgtZjFFS2lvR1gwcXV1QVZQZjVjN2ZUVVljZVRyLTUxWTdxbGJxSndqejJmR2MyYXBIUFFRRUFoaHRNNDNYdjEwNFotWjFGTlJQU0VnWEpzMVh6SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Diem Nguyen awarded 32,000 Candel Therapeutics (CADL) stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPb1habm9Gc0Q3RzFlb0hCMVpfRzgwQnRIQTl1c0VaRU5OTVhtSlU4VzNrVnl5TWtjVUxYZ3dDbFZmbFBFYnRiRm1HLTIyallEQXp1MllNZzdyTlV5dEdhTU5YWVk1cGNBeTh0X0YtMXZKd2o2Nkw2YUVUN3l2bjlieTJBZmtQNUNfOE95aVdnTTRVWVJ4WW5ZeXJMVUZQc2NBeVlrQ1dCMUEtejZFNGJRbnEyNkM4cWli?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics (NASDAQ: CADL) director awarded 32,000 options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPcWstMHpvQlhPUWhFSXFmQVROY19JZ0lYc3ZlRGVYTTh1U1NJLVVWM1BuZ2lrOGszWjFWbUdtZUk2TjNVSUhFVHhTMzRCVy1nTEJ0NEdTVlNvTW1hYWxXTVZCOVUyd3pTVV9FQk83bUdWYldvdy1lR2loLXZQdDI2QWpydmdaZ3ZzQ3lQUTZ2emF6VnFudjliZGJmLTdQQ3RSVTJpWGVMbTV1OGMyZGpKV1BuSEZ3dXJv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/candel-therapeutics-announces-publication-lancet-120500034.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T12:05:00+00:00", "published_display": "02 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New hires at Candel Therapeutics get 63,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcVZqVmhGeWtVY3BHMVNoZjFJMXFqdUhsN0ZaY20takYzcnpfa3dYTlFrc1laSTkyemU1WHBSamRHWkdYalh1OFdqSXVlRUJ6Z3VBalpZdEswUXdRWWlaR3ZUelhENEk0STBiWkgyOGtTMG91YkxJeUw1Z2d3MlFva1h3dVBQYlhkY1ZpamNFUGwtNFRCMzJhcU5DaFNNSWFmNmpCQXdIWmFsOUt6dXNrOFhBUkcwV1N1VHRNeEV4NDM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data", "summary": "", "url": "https://finance.yahoo.com/m/e4d69008-1eb2-3326-af76-22f9b38364a3/candel-therapeutics-eyes.html", "source_name": "MarketBeat", "published_at": "2026-05-20T15:13:00+00:00", "published_display": "20 May 2026 15:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSkpXdklWME51Um5YbXBPaXdtTFRYZXFXQjZ5Z253aVlRYTN1bWNPMWFQNFZrX1FSS3NURENSajFDakI0bkpiVFo0eWdoRmZQVVJOZUViVWFhdEE4MWc5QjlySVA3OEoyU0dNeW9VcWpQZGQ5dTgyWFQwTEY5MllzV3VyUThKQllpWDRoaWdWYm1QalBqTU5hRzl4ZDJqMGNuNWc?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 prostate cancer data highlight Candel Therapeutics (NASDAQ: CADL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOUmdsOTVheXJ1dVhIeWliR0toRlhWNTl2YUR0eDRkRFZNR0ZiYmgwYVVjZmpNTWwzdFo1dWpGc2N1UFRDdEd3T1puWjFJaGNaVjlPYVhOX1hFcWFXMFZ1RFRPM0ZSUDg1eDRfbkN3a2txQjcySlpfamY2cW9hUFVmdWtpRDdmVVo3WnB3S29KYld3YnJQZHBNYWVPR2RmLTZJdmVZM1BLam5OWjhCWS1DSXd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new Candel hires get options to buy 29,400 shares at $6.18", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZGpKRV9hTW9ITUZhZV9QRUc5WHl3TE5aVER2amxTQ3ViWWc1cnNhcnRubU1sR01ySlBMcXV1SS1SSFJsWGVKcE91S1Q4V1hxX3gxRlFfS053TmxMeWoyejVtcC1pNHhqejN4LWRMN3YxYUkyeGo5UG1iVzVCZzVhTUdnTzF3VlBGSnRoZVlRZk1iTGRoakhqUElka1VXbDZvQm1KT3piVEhOTnp3eWc2eUNQenlrc1Ayei1JTl92V1A?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel picks EVERSANA over building its own sales force for prostate launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPeDFlbGpoWGFzWktQVFdLTXRURGRreXZDQ3d1UzY0ejdQWTFCaWJvam5vdEtZeGQ0YWZCc1RmRHNqLURVZngxdDFuRG1sdE9UaU5RNUU0dm92NGpRdlRaME5keVJkbExGd1hmSDJ3RTJ6NURVMENqai16Wm1FRjlQMFhNa3UxT2l1T1pLeVdQcmN2R1Z3Y0p2NklaMzIwRDBPTXNUMDZzS05nOFJlQndHSEN4WVNJcWFu?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVm5ad2pGWGplcTdaNkM3NlNXenNxNlk4UUJPbVpwZWNxS3BOR0YwalRCbGFnVF9Ga3BZU3VIaTNuNnduaUE4aGRHYjA0UEhTdXk1bVl2Ym5KbUNyMDBSTUU2M05INVJqc2wwclI2MHBzR1UtbTdQS0U5Smg5TmhjQmFYMHVGSkZmZkxxZkpOR1pHWl95cllTdjFOYW1TUWFUUXZHX1VsZ1A?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQclRKVi1aQ2hyNUo0aEl5bGJmMmlVdjVQdUZVZGFWdUpUcGN6Q3prVTljNEhpOC1DMkRaV1h6LXBTRWFpUnNNVE1fNDE4LWFESkFBLWpMRWJlODBra1NEZGczNHE1cUY1cU1UZXhRRVpNaC1ZX1FoWHQ1c0V2QW9vZ0U3cEdTRS13aDFwNVNmazRXNDkwaXBsZUJTbFVvd24xamR3VzhLc3EtcEpyaGtVYTdPVkx5bVkydmxvZHZLUlVIVWdwV2xKcTQ1U1Zhei14dTI4OHA1RWdQaUpGLTNfdVRGNW1BQUwz0gHuAUFVX3lxTE1lTktOV1pxQkYzNkJkMWM2VzdGeFUxUHV2RlIyYi1NSVFGNjVGbzhBY1plel9HcUg1ZnBHeGw2dWV1OHl3SGk0eUQ2cnZhWXNSSnBfX2FHRGRLa3V2TFcwdmFMRTVNNFprX09NUzViUGEwUi1CSWUyYklJZ0ZHTXNDRm9zZkUwcjV5N0VDZVdCbHdEM0RsQVU1YkRNa3pPSHAxLTdRU0tWb2JLWm5sQzcyNXFpb0hCaWJUZklXdFdOYXVaOVRsYmhLTWgzY0k0Uzcyd2g3b3pvajVoZURaaHZjaFBkc0Z1MXNqcnk4Q0E?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report\u2014Grail, Candel", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQaUJEWURHeVJpYzNaV1NKLXF2TW5MQ1hqaUJrZ1BfRVRyTTZuRFR5dzZjajBudF9fR3A5QmUxQ0NDd1UwWDdFTUpNYmw2YUgtMlZEaVE0RXMtSTN1X19FNE01Q1BuLUJjeEFuMHJIenNQUThiS3pybFFWQUstS0E1R3pHOGk1NWZmUjN2QXA2bDBhLXRBWmlrZWdmbkVXLVZuellJaTZPeXl5dktkc1VlUW56cDQyQld2ZTU1UGhwZE9OYU9aMkVxSms1bEtjLWZTLXJCSWpxMDBkRDR1XzVYLVVCV0V6M2lHZkZ4QldGdVhsck9YOWFIUlhjd1E1Tndo?oc=5", "source_name": "Benzinga", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_gFBVV95cUxONU1rSzBKczVDT3VjcW0zaUpmdVVvVGtOMGg5czhCcXk0RFBNcmR2MTdONjZUV0k0Zi1DbjJnaGdEOUhyTGZpTzI0dnhfdTcxSWxzSlUzNkgtYWhiWnA4TUkzOXBKcmVNQWNyQzZxX2p2ejh5WXNzeC1DN0gxdlp0aWFHTFNFNVJqZU81aXczN1lPVVNzelJTU0NmbloxSWpWNFctcnhCS0ZhNWFaM3FiLS0yb1A2dndWWWRCUkxwUENrY0JBci1EeGlkMTRucjdFTkNzTU5lOGRGamx4TG5GeWZrb0dPRTh4NjA4YThwZ3BYUHBtLTZOZHpNb21PZw?oc=5", "source_name": "Proactive financial news", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcVVpTFh4d0hqVnhSZW54YWFmRUgwUWJBVXdnaktVNU9MUVpxeWZNaVo1QkFSbDhaOHhPanByY3lCYi1vSVdBdzM2Y09mWGswVFhZTjcwdW5WRnZKaE9nMjhfTjN3TC1TNFp3V0ptOTZaVXN4UXhzbS1UZGJDdW41VkRhSXFTWXpKYlpfZWJ2dUZNWVZGNi1GRGhEbFZXUQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-02-07T08:00:00+00:00", "published_display": "07 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 58, "sentiment_summary": {"positive": 18, "negative": 3, "neutral": 37, "score": 57, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 21.05, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 9.49, "latest_week": "2026-07-10", "one_week_move": -3.5, "four_week_move": 10.9, "twelve_week_move": 49.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.20664, "market_dynamics_buy_signal": false, "relative_strength": 32.849893, "fair_value_gap": 83.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.4147, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.5% over one week, +10.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 17}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 3}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.5% over one week, +10.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Candel Therapeutics Reported Better-Than-Feared Q1 Loss \u2013 But All Eyes Turn To This Pivotal Event Tomorrow"}], "updated_at": "2026-07-18T03:42:17.361576+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}